



Lelystad, 30 March 2009

MR VISSER RESIGNS AS A MEMBER OF THE SUPERVISORY BOARD

Mr T.J.A. Visser (member of the supervisory board of Fornix BioSciences since august 2003) has announced to resign as a member of the supervisory board of Fornix BioSciences N.V during the coming annual general meeting of shareholders, which will be held on Friday 24 April 2009. Mr T.J.A. Visser, founder of Dr. Fisher Farma B.V., former shareholder and ex-CEO has made this decision due to private circumstances and other occupations.

Besides, the company announces that as from today the annual report 2008 is available on the website www.fornix.nl.

Profile of Fornix BioSciences N.V.

Fornix BioSciences N.V. is a listed company (Euronext Amsterdam, code AFORBI) which engages in the development and sale of diagnostics and therapeutic allergen products and the distribution of medical aids and medical and nursing consumables. Fornix BioSciences N.V. has sites in Lelystad, Beuningen and Hamburg. The company currently has a workforce of around 130 and is active mainly in the Netherlands and Germany.

Its activities are carries on by two divisions, which in turn are made up of operating companies.

The Allergy Division, which consists of Artu Biologicals Europe and, since 1 June 2007, Artu Biologicals Deutschland, is the most profitable division. Its activities include the development, production and sale of a wide range of patient-friendly immunotherapeutic products, under the Oralgen®, Igevac® and other trade names. These products are used in the causal treatment of allergies triggered by various allergens, such as grass and tree pollen and house dust mites. The development programme is supported by high-quality R&D activities and pan-European clinical studies of the effectiveness of the various products.

The Medical Aids Division, which consists of Laprolan in Beuningen, engages in the sale, marketing and distribution of a wide range of medical aids and medical and nursing consumables.

END OF PRESS RELEASE

For further information, please contact:
C.L. Bergman, CEO, Fornix BioSciences N.V.
Tel. +31 (0) 320 26 77 99
Website: www.fornix.nl